2026-09-13

Presbyopia Market to Grow at a CAGR of 4.9% Through 2036, Driven by an Expanding Treatment Landscape, Reports DelveInsight

The global presbyopia market is projected to grow at a CAGR of 4.9% during the forecast period from 2026 to 2036, supported by the rising aging population, increasing prevalence of age-related near vision impairment, greater disease awareness, and improved diagnosis rates. The expanding pipeline of pharmacological therapies and medical devices is also expected to create new opportunities in the presbyopia treatment landscape.

Emerging therapies and devices, including Phentolamine (Opus Genetics/Viatris), MicroLine (Pilocarpine Ophthalmic) (Eyenovia), GLK-302 (Glaukos Corporation), CorVision (Intrastromal Corneal Inlay) (LinkoCare Life Sciences AB), and the riboflavin/UV-A medical device (RegenSight), are being evaluated for their potential to address unmet needs in presbyopia management.

According to DelveInsight's recently published Presbyopia Market Insights report, the study provides a comprehensive assessment of current treatment practices, marketed and emerging therapies, market shares, epidemiology, and historical and forecasted market sizes from 2022 to 2036 across the seven major markets, including the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Presbyopia Market Key Highlights

The presbyopia market in the seven major markets was valued at approximately USD 11 billion in 2025.
The United States accounted for approximately 50% of the total presbyopia treatment market in 2025, representing the largest share among the seven major markets.
The total number of prevalent presbyopia cases across the seven major markets was estimated at nearly 290,000 cases in 2025 and is projected to increase during the forecast period.
Leading companies involved in the presbyopia treatment landscape include Opus Genetics, Viatris, Eyenovia, Glaukos Corporation, LinkoCare Life Sciences AB, RegenSight, AbbVie, Orasis Pharmaceuticals, LENZ Therapeutics, and Tenpoint Therapeutics, among others.
Key emerging therapies and devices include Phentolamine, MicroLine, GLK-302, CorVision, and the riboflavin/UV-A medical device.
MicroLine (Eyenovia) is an emerging topical presbyopia treatment candidate that is projected in the report to potentially receive approval in the United States by 2027.

Discover more about the Presbyopia Market:
https://www.delveinsight.com/report-store/presbyopia-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Key Factors Driving the Presbyopia Market

Rising Presbyopia Prevalence

In 2025, the United States accounted for approximately 125,000 diagnosed prevalent cases of presbyopia. The diagnosed patient population is expected to increase during the forecast period, supported by population growth, improvements in diagnostic practices, and greater awareness of age-related vision impairment.

Growing Aging Population

The increasing global population of adults aged 40 years and older is a major contributor to the growth of the presbyopia market. As the eye's natural lens gradually loses flexibility with age, the ability to focus on nearby objects declines, increasing the demand for vision correction and treatment options.

Technological Advancements in Vision Correction

Advancements in multifocal lenses, laser-assisted procedures, corneal inlays, and presbyopia-correcting intraocular lenses are expanding the available treatment options. These innovations aim to improve visual outcomes, treatment precision, and patient satisfaction.

Expansion of Emerging Therapies and Devices

The presbyopia market is expected to evolve with the development of novel pharmacological therapies and medical devices. Key candidates include Phentolamine, MicroLine, GLK-302, CorVision, and the riboflavin/UV-A medical device, among others.

Presbyopia Market Analysis

Presbyopia management includes corrective eyewear, contact lenses, prescription eye drops, and surgical interventions. Treatment selection depends on the severity of near-vision impairment, patient preferences, and clinical considerations.

Commonly used surgical approaches include:

Conductive Keratoplasty
LASIK
LASEK
Photorefractive Keratectomy (PRK)
Lens-based procedures and presbyopia-correcting intraocular lenses

The United States currently represents the largest market among the seven major markets and has several approved pharmacological treatment options, including VUITY, QLOSI, VIZZ, and YUVEZZI, according to the supplied market analysis.

The report also highlights the continued development of therapies with novel mechanisms of action. However, the late-stage presbyopia pipeline remains relatively limited, with candidates such as Phentolamine and MicroLine identified as potential future contributors to market growth.

Learn more about the Presbyopia Treatment Market:
https://www.delveinsight.com/report-store/presbyopia-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Presbyopia Competitive Landscape

The presbyopia competitive landscape includes pharmaceutical companies, biotechnology firms, and medical device developers working to improve near-vision correction and address limitations associated with existing treatment approaches.

Key emerging therapies and devices include:

Phentolamine Ophthalmic Solution 0.75%: Opus Genetics/Viatris
MicroLine (Pilocarpine Ophthalmic): Eyenovia
GLK-302: Glaukos Corporation
CorVision (Intrastromal Corneal Inlay): LinkoCare Life Sciences AB
Riboflavin/UV-A Medical Device: RegenSight

Phentolamine Ophthalmic Solution 0.75%

Phentolamine Ophthalmic Solution 0.75% is an investigational treatment being developed for presbyopia. It is designed to act as a non-selective alpha-adrenergic antagonist and aims to improve near vision through changes in pupil size without directly affecting the ciliary muscle.

According to the supplied market information, the candidate was under regulatory assessment following the submission of a supplemental New Drug Application in early 2026. The company anticipated a regulatory decision by the end of 2026.

CorVision

CorVision, developed by LinkoCare Life Sciences AB, is a bioengineered corneal microlens designed for presbyopia correction. The collagen-based device is intended for implantation into a corneal pocket and aims to provide an alternative approach to near-vision correction.

The development of pharmacological therapies and medical devices such as Phentolamine and CorVision may contribute to the evolution of the presbyopia treatment landscape, subject to clinical outcomes and regulatory decisions.

Explore the Presbyopia Competitive Landscape:
https://www.delveinsight.com/report-store/presbyopia-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Recent Developments in the Presbyopia Market

January 2026: Tenpoint Therapeutics announced that it had secured USD 235 million through the closing of a Series B preferred stock financing and a credit facility. The funding is intended to support the commercialization of YUVEZZI.
September 2025: LENZ Therapeutics announced the availability of VIZZ (aceclidine ophthalmic solution) 1.44% in the United States. The company also announced the initiation of professional product sample distribution to optometrists and ophthalmologists.
July 2025: The US Food and Drug Administration approved VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in adults, according to the supplied market information.

What Is Presbyopia?

Presbyopia is an age-related vision condition in which the eye gradually loses its ability to focus on nearby objects. It commonly develops after the age of 40 as the natural lens becomes less flexible.

Individuals with presbyopia may experience blurred near vision, eye strain, headaches, and difficulty reading or performing close-up tasks. The condition can be managed through reading glasses, bifocals, contact lenses, prescription eye drops, and surgical treatment options.

Presbyopia Epidemiology Segmentation

The Presbyopia Market Insights report provides an assessment of the historical and forecasted patient population across the seven major markets for the period 2022–2036.

In 2025, the United States accounted for the highest number of diagnosed prevalent presbyopia cases among the seven major markets, with approximately 125,000 cases.

The epidemiology analysis includes:

Total prevalent cases of presbyopia
Total diagnosed cases of presbyopia
Age-specific cases of presbyopia
Gender-specific cases of presbyopia
Severity-specific cases of presbyopia
Total treated cases of presbyopia

Explore the Presbyopia Market Report:
https://www.delveinsight.com/report-store/presbyopia-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Presbyopia Market Report Metrics

Study Period: 2022–2036
Coverage: 7MM
Presbyopia Market Size in 2025: USD 11 billion
Key Companies: Opus Genetics, Viatris, Eyenovia, Glaukos Corporation, LinkoCare Life Sciences AB, RegenSight, AbbVie, Orasis Pharmaceuticals, LENZ Therapeutics, Tenpoint Therapeutics, and others.
Key Therapies and Devices: Phentolamine, MicroLine, GLK-302, CorVision, riboflavin/UV-A medical device, VUITY, QLOSI, VIZZ, YUVEZZI, and others.

Scope of the Presbyopia Market Report

The report provides a comprehensive assessment of the presbyopia market, covering:

Therapeutic Assessment: Analysis of marketed and emerging presbyopia therapies.
Market Dynamics: Assessment of market drivers, barriers, and emerging treatment opportunities.
Competitive Intelligence: Evaluation of the competitive landscape, SWOT analysis, and market-entry strategies.
Unmet Needs and Expert Insights: Assessment of unmet needs, key opinion leader perspectives, analyst views, market access, and reimbursement.
Market Forecast: Historical and forecasted market sizes across the seven major markets.

Discover more about the Presbyopia Clinical Pipeline:
https://www.delveinsight.com/report-store/presbyopia-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Presbyopia Market Key Insights
Presbyopia Market Report Introduction
Executive Summary
Key Events
Epidemiology and Market Forecast Methodology
Presbyopia Market Overview at a Glance
Presbyopia: Overview
Guidelines of Presbyopia
Regulation of Medical Devices
Epidemiology and Patient Population
Patient Journey
Marketed Presbyopia Drugs
Emerging Presbyopia Drugs
Marketed Presbyopia Medical Devices
Emerging Presbyopia Medical Devices
Presbyopia Market: Seven Major Market Analysis
Presbyopia Market Unmet Needs
Presbyopia Market SWOT Analysis
Key Opinion Leader Views on Presbyopia
Presbyopia Market Access and Reimbursement
Bibliography

Presbyopia Clinical Trial Analysis Pipeline

Presbyopia Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key presbyopia companies, including Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others.

Myopia Market

Myopia Market Insight, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key myopia companies such as Vyluma, Inc., Sydnexis, Inc., Ocumension Limited, Santen Pharmaceutical, Cloudbreak Therapeutics, Nevakar, Inc., Eyenovia, Stuart Therapeutics, Cellix Bio, JeniVision, Zhaoke Ophthalmology, and others.

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences industry. The company provides comprehensive market research, consulting, and competitive intelligence solutions to support pharmaceutical, biotechnology, and healthcare organizations in making informed business decisions.

Through its subscription-based platform, PharmDelve, DelveInsight provides access to healthcare and pharmaceutical market research reports.

Contact Us

Kanishk

info@delveinsight.com

2026-09-10

Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036)| DelveInsight

The alcohol use disorder market is set to grow due to unmet clinical needs, limited efficacy of current therapies, and rising demand for better-tolerated treatments. Expanding label indications, new regulatory approvals of therapies such as AD04 (ondansetron) (Adial Pharmaceuticals), Brenipatide (LY3537031) (Eli Lilly and Company), MN-166 (ibudilast) (MediciNova), Sunobinop (V117957) [Imbrium Therapeutics (subsidiary of Purdue Pharma)], Pemvidutide (Altimmune), TMP-301/HTL0014242 (Tempero Bio and Nxera Pharma), and others, along with increasing awareness and reduced stigma, are expected to boost access and adoption, driving significant market growth.

Recently published Alcohol Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, alcohol use disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets including the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Alcohol Use Disorder Market Summary

The market size for alcohol use disorder was estimated at USD 1.1 billion in the 7MM in 2025.
The United States accounted for the largest alcohol use disorder treatment market size in 2025, compared with other major markets, including the EU4 countries, the United Kingdom, and Japan.
There were 25.6 million 12-month diagnosed prevalent cases of AUD in the US in 2025, which are projected to decrease by 2036.
Key alcohol use disorder companies, including Adial Pharmaceuticals, Eli Lilly and Company, MediciNova, Imbrium Therapeutics (subsidiary of Purdue Pharma), Altimmune, Tempero Bio, Nxera Pharma, The Pop Test & Palisades Therapeutics, and others, are actively working on innovative alcohol use disorder drugs.
Key alcohol use disorder therapies in clinical trials include AD04 (ondansetron), Brenipatide (LY3537031), MN-166 (ibudilast), Sunobinop (V117957), Pemvidutide, TMP-301/HTL0014242, PT150, and others.
Among therapies in the US, VIVITROL (naltrexone) held the highest market share in 2025, while AD04 is projected to capture the largest market share by 2036.

Discover more about the Alcohol Use Disorder market forecast @
https://www.delveinsight.com/report-store/alcohol-use-disorder-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Key Factors Driving the Growth of the Alcohol Use Disorder Market

Growing Awareness and Early AUD Diagnosis

Public health campaigns, physician education, and increased awareness about the harmful effects of alcohol abuse are contributing to earlier diagnosis and intervention. As more patients seek treatment, the alcohol use disorder market is expected to benefit from increasing diagnosis and treatment uptake.

Rising Focus on Harm Reduction and Personalized Care

Shifts in treatment paradigms toward harm reduction strategies, personalized therapy, and combination approaches involving behavioral and pharmacological interventions are creating new opportunities in the AUD market and encouraging greater adoption of approved therapies.

Strong AUD Clinical Trial Activity

Several companies are advancing therapies through clinical development. Key pipeline candidates include AD04 (Adial Pharmaceuticals), Sunobinop (Imbrium Therapeutics [subsidiary of Purdue Pharma]), Ibudilast (MediciNova), TMP-301/HTL0014242 (Tempero Bio and Nxera Pharma), Pemvidutide (Altimmune), PT150 (The Pop Test & Palisades Therapeutics), and others.

Aparna Thakur, Project Manager of Forecasting at DelveInsight, said that the exploration of novel mechanisms in AUD treatment, such as 5-HT3 antagonism, NOP receptor modulation, mGluR5 NAM activity, and dual GLP-1/glucagon receptor agonism, highlights significant opportunities for developers to enter a space with high unmet need and differentiate their pipelines through innovative, non-traditional targets.

Alcohol Use Disorder Market Analysis

The United States has witnessed a significant decline in AUD, along with corresponding reductions in binge drinking, heavy alcohol consumption, and underage drinking among individuals aged 12–20 years. These trends underscore growing momentum toward recovery and improved alcohol-related health outcomes.

The treatment landscape for AUD began with the approval of ANTABUSE (disulfiram) in 1951, the first FDA-approved medication for alcohol dependence. For many years, it remained the only pharmacological option available, laying the foundation for medical management of AUD.

Although several therapies have since been approved, including acamprosate, disulfiram, naltrexone, VIVITROL, SELINCRO, and baclofen, treatment uptake remains substantially low, leaving a significant proportion of affected individuals untreated.

Currently available pharmacotherapies for AUD include CAMPRAL (acamprosate), ANTABUSE (disulfiram), REVIA (oral naltrexone), VIVITROL (extended-release injectable naltrexone), SELINCRO (nalmefene), and BACLOCUR (baclofen). The widespread availability of generic formulations for most of these medications has improved patient access and affordability.

While the AUD pipeline remains relatively limited, the therapeutic market is expected to expand in the coming years. Several companies are advancing innovative candidates through clinical development, including Adial Pharmaceuticals (AD04), MediciNova (MN-166), Altimmune (pemvidutide), Imbrium Therapeutics (sunobinop), Tempero Bio and Nxera Pharma (TMP-301/HTL0014242), and The Pop Test & Palisades Therapeutics (PT150), among others.

Learn more about the late-stage AUD assets that could transform the market @ Alcohol Use Disorder Treatment Market

Alcohol Use Disorder Competitive Landscape

Some of the AUD drugs under development include AD04 (ondansetron) (Adial Pharmaceuticals), Brenipatide (LY3537031) (Eli Lilly and Company), MN-166 (ibudilast) (MediciNova), Sunobinop (V117957) [Imbrium Therapeutics (subsidiary of Purdue Pharma)], Pemvidutide (Altimmune), TMP-301/HTL0014242 (Tempero Bio and Nxera Pharma), PT150 (The Pop Test & Palisades Therapeutics), and others.

Adial Pharmaceuticals' AD04

AD04 is a genetically guided therapy being developed for the treatment of AUD. The candidate is currently under evaluation in a Phase III clinical trial targeting individuals with specific genetic profiles identified through Adial's proprietary companion diagnostic test.

The company has established a genetic biomarker-based diagnostic assay to identify patients most likely to benefit from AD04. This test was implemented in the large-scale ONWARD randomized controlled trial and is expected to play a role in future studies, supporting regulatory approval and commercialization alongside AD04.

Eli Lilly and Company's Brenipatide

Brenipatide is a biologic therapy that functions as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is being investigated as a potential treatment for AUD and is currently in Phase III clinical development.

Developed by Eli Lilly, Brenipatide represents the company's expansion into indications beyond obesity, including alcohol use disorder, opioid dependence, and asthma.

MediciNova's MN-166

MN-166 is an orally administered small-molecule agent that inhibits phosphodiesterase-4 (PDE4) and modulates inflammatory cytokines such as macrophage migration inhibitory factor (MIF). The therapy is presently undergoing Phase II clinical evaluation for AUD and is being explored for its potential to address neuroinflammatory mechanisms associated with the disorder.

Altimmune's Pemvidutide

Pemvidutide is an investigational peptide-based therapy designed as a balanced 1:1 dual agonist of GLP-1 and glucagon receptors. The candidate is being developed across multiple indications, including Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (AALD), and obesity.

The anticipated launch of these emerging alcohol use disorder therapies is expected to transform the AUD market landscape in the coming years. As these therapies continue to mature and potentially gain regulatory approval, they could reshape treatment approaches and create opportunities for medical innovation and market growth.

To know more about companies working on GLP-1 drugs for AUD @ Alcohol Use Disorder Medication

Recent Developments in the Alcohol Use Disorder Market

March 2026: Adial Pharmaceuticals entered into a collaboration framework agreement with Molteni Farmaceutici for a proposed exclusive partnership covering the commercialization of AD04 in Europe.
January 2026: Adial Pharmaceuticals announced the publication of the international patent application for AD04, filed in July 2024. AD04 is the company's lead investigational genetically targeted serotonin-3 receptor antagonist therapeutic agent for the treatment of AUD in heavy-drinking patients. The patent, once granted, is expected to protect Adial's core assets through at least 2045.
November 2025: Altimmune announced the completion of patient enrollment in RECLAIM, a Phase II clinical trial evaluating pemvidutide in adults with AUD. The trial is evaluating pemvidutide in approximately 100 patients across sites in the US. Altimmune expects to announce topline results from the trial in 2026.
July 2025: Clearmind Medicine announced the expansion of its Phase I/IIa clinical trial evaluating CMND-100 for AUD, marked by the activation of an additional site at Johns Hopkins University School of Medicine and enrollment of the first participant at this location.

What is Alcohol Use Disorder?

Alcohol use disorder (AUD) is a chronic relapsing brain disorder characterized by an impaired ability to control or stop alcohol consumption despite adverse social, occupational, or health consequences. The condition ranges from mild to severe and is associated with physical dependence, tolerance, withdrawal symptoms, and compulsive alcohol-seeking behavior.

AUD can significantly impact an individual's mental and physical health and increase the risk of liver disease, cardiovascular disorders, neurological complications, depression, and premature mortality.

Alcohol Use Disorder Epidemiology Segmentation

The alcohol use disorder epidemiology section provides insights into the historical and current AUD patient pool and forecasted trends for the leading markets.

The 12-month diagnosed prevalence of AUD in the United States has shown a modest decline in recent years, decreasing from approximately 10.6% in 2021 to 9.7% in 2025.

The alcohol use disorder market report provides epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

12-month diagnosed prevalent cases of AUD
Gender-specific diagnosed prevalent cases of AUD
Age-specific diagnosed prevalent cases of AUD
Severity-specific diagnosed prevalent cases of AUD
Total treated cases of AUD

Download the report to understand the addressable patient population for AUD drugs @ Alcohol Use Disorder Treatment Options

Alcohol Use Disorder Market Report Metrics

Study Period: 2022–2036
Coverage: 7MM
Key Companies: Adial Pharmaceuticals, Eli Lilly and Company, MediciNova, Imbrium Therapeutics, Altimmune, Tempero Bio, Nxera Pharma, Alkermes, The Pop Test, Palisades Therapeutics, and others |
Key Therapies: AD04 (ondansetron), Brenipatide (LY3537031), MN-166 (ibudilast), Sunobinop (V117957), Pemvidutide, TMP-301/HTL0014242, PT150, VIVITROL, and others

Scope of the Alcohol Use Disorder Market Report

Alcohol Use Disorder Patient Population Forecast
Alcohol Use Disorder Therapeutics Market Size
Alcohol Use Disorder Pipeline Analysis
Alcohol Use Disorder Market Size and Trends
Alcohol Use Disorder Market Opportunity
Alcohol Use Disorder Market Unmet Needs
KOLs' Views on Alcohol Use Disorder
Alcohol Use Disorder Market Access and Reimbursement

Discover more about the most promising alcohol use disorder drugs in development @ Alcohol Use Disorder Clinical Trials

Alcohol Use Disorder Market Key Insights
Alcohol Use Disorder Market Report Introduction
Executive Summary of Alcohol Use Disorder (AUD)
Key Events
Epidemiology and Market Forecast Methodology
Alcohol Use Disorder (AUD) Market Overview at a Glance
Disease Background and Overview of Alcohol Use Disorder (AUD)
Treatment of Alcohol Use Disorder (AUD)
Epidemiology and Patient Population of Alcohol Use Disorder (AUD)
Patient Journey of Alcohol Use Disorder (AUD)
Marketed AUD Therapies
Emerging AUD Therapies
Alcohol Use Disorder Market: The 7MM Market Analysis
Unmet Needs of Alcohol Use Disorder (AUD)
SWOT Analysis of Alcohol Use Disorder (AUD)
KOL Views of Alcohol Use Disorder (AUD)
Market Access and Reimbursement of Alcohol Use Disorder (AUD)
Bibliography
Alcohol Use Disorder Market Report Methodology

Alcohol Use Disorder Clinical Trial Analysis

Alcohol Use Disorder Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and key AUD companies, including Adial Pharmaceuticals, Solvonis Therapeutics, MediciNova, Kinnov Therapeutics, Tonix Pharmaceuticals, Afasci Inc., Tempero Bio, Clearmind Medicine, BioCorRx, BioXcel Therapeutics, Biomed Industries, Lophora, and others.

GLP-1 Agonists Market

GLP-1 Agonists Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key GLP-1 agonists companies, including Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, Amgen, Viking Therapeutics, Regor Therapeutics, Carmot Therapeutics, Roche, GlaxoSmithKline, and Sanofi, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all healthcare and pharma market research reports through its subscription-based platform, PharmDelve.

Contact Us

Kanishk

info@delveinsight.com

2026-09-10

Endometriosis Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight

DelveInsight's “Endometriosis Pipeline Insight 2026” report provides comprehensive insights into the endometriosis pipeline landscape, covering 20+ companies and 22+ pipeline drugs. The report includes detailed profiles of clinical- and nonclinical-stage pipeline therapies, along with therapeutic assessments by product type, development stage, route of administration, and molecule type. It also highlights inactive pipeline products and key developments shaping the treatment landscape.

Request a sample and discover the recent advances in Endometriosis Drugs:
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Key Takeaways from the Endometriosis Pipeline Report

In August 2026, Medicus Pharma received UAE regulatory clearance to initiate its Phase IIa PRECISION-E2 trial evaluating teverelix in women with moderate-to-severe endometriosis using a genomics-guided precision medicine approach.
In August 2026, Sunshine Biopharma announced Canadian approval for its 2 mg generic dienogest tablets for pelvic pain associated with endometriosis, with commercial availability expected by the end of 2026.
DelveInsight's Endometriosis Pipeline report identifies a robust development landscape, with 20+ active companies working on 22+ pipeline therapies.
Leading endometriosis companies include Hope Medicine (Nanjing) Co., Ltd., TiumBio, EpicentRx, Ferring Pharmaceuticals, Gesynta Pharma, VaRi Bioscience, Viramal, Tanabe Pharma Corporation, Gynica, Absci Corp, and others.
Promising endometriosis therapies include Triptorelin Embonate, Implantable gestrinone, KLH-2109, Oral Dienogest, Leuprorelin acetate, SN132D, OG-6219, and others.

Find out more about Endometriosis Drugs:
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Endometriosis Overview

Endometriosis is characterized by the presence of endometrial gland- and stroma-like lesions outside the uterus. These lesions can occur as peritoneal lesions, superficial implants, cysts, or deep infiltrating disease.

Although the definitive cause of endometriosis remains unclear, several hypotheses have been proposed regarding the development of endometriotic lesions. One potential mechanism involves retrograde menstruation, in which endometrial tissue flows through the fallopian tubes into the pelvic cavity. Retrograde flow, along with possible hematogenous or lymphatic circulation, may contribute to the implantation of endometrial tissue at ectopic sites.

Endometriosis Emerging Drugs

HMI-115: Hope Medicine (Nanjing) Co., Ltd.

HMI-115 is a first-in-class monoclonal antibody targeting the prolactin receptor (PRLR), for which Hope Medicine holds global rights. The candidate is being developed for multiple indications, including endometriosis and androgenic alopecia, as well as other chronic diseases.

HMI-115 has demonstrated favorable characteristics in animal models, including non-human primate models, as well as human safety data. The drug is currently in Phase III development for the treatment of endometriosis.

Merigolix: TiumBio

Merigolix (TU2670) is an oral GnRH antagonist designed to bind to pituitary receptors and suppress estradiol levels. Unlike GnRH agonists, which are generally administered through injections and can suppress sex hormones to menopausal levels, TU2670 is designed to provide oral administration while suppressing hormone levels to a therapeutic range.

This approach may help address treatment-related side effects and improve convenience. The mechanism may also support potential expansion into indications such as precocious puberty, in vitro fertilization, and infertility treatment.

Merigolix is currently being evaluated in Phase II clinical development for endometriosis.

Nibrozetone (RRx-001): EpicentRx

Nibrozetone, also known as RRx-001, is an investigational therapy with anti-inflammatory and antioxidant properties. Its mechanism includes the release of metabolites such as nitric oxide and other nitrogen-centered free radicals in hypoxic environments.

In non-hypoxic environments, RRx-001 has demonstrated anti-inflammatory and antioxidant activity through mechanisms involving the NLRP3 inflammasome and Nrf2 pathways. The therapy is currently in Phase I development for endometriosis.

What the Endometriosis Pipeline Report Provides

The Endometriosis Pipeline Insight report provides detailed analysis of the evolving therapeutic landscape, including:

Detailed insights into companies developing therapies for endometriosis and the therapies being developed by each company.
Assessment of therapeutic candidates across early-, mid-, and late-stage development.
Analysis of companies involved in targeted therapeutic development, including active and inactive, dormant, or discontinued projects.
Evaluation of pipeline therapies based on development stage, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
Detailed analysis of company-company collaborations, company-academia collaborations, licensing agreements, and financing activities supporting future development.

Learn more about Endometriosis drug development opportunities:
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Endometriosis Companies

The key companies active in the endometriosis pipeline include:

Hope Medicine (Nanjing) Co., Ltd., TiumBio, EpicentRx, Ferring Pharmaceuticals, Gesynta Pharma, VaRi Bioscience, Viramal, Tanabe Pharma Corporation, Gynica, Absci Corp, and others.

Endometriosis Pipeline by Route of Administration

The report provides a therapeutic assessment of pipeline therapies according to their route of administration. Products are categorized into:

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Endometriosis Pipeline by Molecule Type

Pipeline products are also categorized according to molecule type, including:

Recombinant fusion proteins
Small molecules
Monoclonal antibodies
Peptides
Polymers
Gene therapies

Stay informed about emerging Endometriosis treatments:
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Scope of the Endometriosis Pipeline Report

Coverage: Global
Key Endometriosis Companies: Hope Medicine (Nanjing) Co., Ltd., TiumBio, EpicentRx, Ferring Pharmaceuticals, Gesynta Pharma, VaRi Bioscience, Viramal, Tanabe Pharma Corporation, Gynica, Absci Corp, and others.
Key Endometriosis Therapies: Triptorelin Embonate, Implantable gestrinone, KLH-2109, Oral Dienogest, Leuprorelin acetate, SN132D, OG-6219, and others.
Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment by Clinical Stage: Discovery, Preclinical, Phase I, Phase II, Phase III

Dive deeper into emerging Endometriosis Treatments:
https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Introduction
Executive Summary
Endometriosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Endometriosis: DelveInsight's Analytical Perspective
Late-Stage Products (Phase III)
Estelle: Gedeon Richter
Mid-Stage Products (Phase II)
GenSci048: Changchun GeneScience Pharmaceutical Co., Ltd.
Early-Stage Products (Phase I)
Preclinical and Discovery-Stage Products
MP137P: NETRIS Pharma
Inactive Products
Endometriosis Key Companies
Endometriosis Key Products
Endometriosis: Unmet Needs
Endometriosis: Market Drivers and Barriers
Endometriosis: Future Perspectives and Conclusion
Endometriosis Analyst Views
Endometriosis Key Companies
Appendix

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm providing high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry professionals and expertise across the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients worldwide.

DelveInsight provides comprehensive healthcare and pharmaceutical market research, pipeline intelligence, epidemiology, competitive intelligence, and consulting solutions designed to help life sciences companies understand evolving markets and identify emerging opportunities.

Contact Us

Kanishk

info@delveinsight.com

2026-09-09

Alcohol-associated Liver Disease Market Gearing Up for Outstanding Expansion at a CAGR of 31.1% During the Forecast Period (2026–2036) | DelveInsight

The Alcohol-associated Liver Disease (ALD) Market is projected to witness outstanding expansion during the forecast period, driven by gradual therapeutic innovation, rising disease awareness, and increasing emphasis on targeted, mechanism-based treatment approaches. The anticipated emergence of mid-stage therapies such as Larsucosterol (DUR-928) (Bausch Health), GSK4532990 (GSK), INT-787 [Alfasigma (Intercept Pharmaceuticals)], Pemvidutide (Altimmune), NTR-101 (Nterica), and others is expected to intensify competition across the ALD treatment landscape through 2036.

According to DelveInsight's recently published Alcohol-associated Liver Disease Market Insights report, the report provides a comprehensive assessment of current treatment practices, emerging therapies, individual therapy market shares, epidemiology, and historical and forecasted market sizes from 2022 to 2036 across the 7MM, comprising the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Alcohol-associated Liver Disease Market Key Highlights

The ALD market in the 7MM was valued at approximately USD 145 million in 2025.
The United States represented approximately 59% of the total 7MM ALD market in 2025.
The total number of diagnosed prevalent cases of ALD across the 7MM reached approximately 12.1 million in 2025.
Leading companies developing ALD therapies include Bausch Health, GSK, Alfasigma (Intercept Pharmaceuticals), Altimmune, Nterica, and others.
Promising therapies in clinical development include Larsucosterol (DUR-928), GSK4532990, INT-787, Pemvidutide, NTR-101, and others.
Larsucosterol is estimated to generate the highest ALD therapy revenue in the United States by 2036.
The ALD market is projected to grow at a CAGR of 31.1% during 2026–2036.

Discover the future of the Alcohol-associated Liver Disease treatment market @ Alcohol-associated Liver Disease Market Report

Key Factors Driving the Alcohol-associated Liver Disease Market

Rising Global Alcohol Consumption and Changing Drinking Patterns

Increasing alcohol consumption and changing drinking patterns remain important contributors to the growing burden of ALD. Rising alcohol use among women, combined with potential biological differences in susceptibility to liver injury, further underscores the need for targeted and scalable treatment approaches.

Increasing Overlap Between ALD, Obesity, and Metabolic Dysfunction

The growing recognition of the relationship between ALD and metabolic conditions such as obesity and insulin resistance is creating opportunities for metabolic-focused treatments. GLP-1-based therapies and combination approaches could become increasingly relevant as researchers explore the interaction between alcohol-related and metabolic liver injury.

Emergence of Microbiome-based and Precision Medicine Approaches

The ALD pipeline is gradually moving toward mechanism-based therapies targeting inflammation, fibrosis, metabolic dysfunction, and other disease drivers. This shift reflects increasing interest in precision medicine and innovative therapeutic modalities for patients with substantial unmet medical needs.

Diversification of Therapeutic Approaches

The emerging ALD landscape extends beyond traditional corticosteroid-based management and includes diverse approaches such as GLP-1/glucagon dual agonists, FXR agonists, RNA interference therapies, and microbiome-directed therapies. These candidates are designed to address upstream mechanisms involving metabolism, inflammation, fibrosis, and microbial dysbiosis.

Expected Launch of Emerging ALD Therapies

The ALD market is expected to evolve as emerging therapies progress through clinical development and potentially reach the market. Key candidates include Larsucosterol (DUR-928), GSK4532990, INT-787, Pemvidutide, NTR-101, and others.

Alcohol-associated Liver Disease Market Analysis

Management of ALD remains largely supportive and depends on disease severity, with long-term alcohol abstinence serving as a cornerstone of care.

For patients with severe alcohol-associated hepatitis, corticosteroids may be used in selected cases, although their benefits are variable and primarily associated with short-term survival. Nutritional support, management of complications, and multidisciplinary care remain important components of treatment.

For eligible patients with advanced disease and liver failure, liver transplantation remains the most effective strategy for significantly improving survival.

Despite the considerable clinical and socioeconomic burden of ALD, there are currently no FDA-approved therapies that directly modify the underlying disease progression. Existing treatment approaches primarily focus on managing symptoms, preventing complications, and addressing the consequences of progressive liver injury.

The therapeutic landscape is nevertheless evolving, with investigational candidates advancing through early- and mid-stage clinical development. These therapies aim to address key disease mechanisms involving metabolic dysfunction, inflammation, fibrosis, and other pathological processes.

Alcohol-associated Liver Disease Competitive Landscape

The ALD pipeline includes several investigational therapies with differentiated mechanisms of action. Key candidates include:

Bausch Health's Larsucosterol (DUR-928)

Larsucosterol is an endogenous sulfated oxysterol and epigenetic regulator designed to inhibit DNA methyltransferases (DNMT1, DNMT3a, and DNMT3b). Through its effects on inflammatory signaling, lipid metabolism, and cellular stress pathways, the therapy is being developed to reduce liver injury and support liver repair in alcohol-associated hepatitis.

The US FDA has granted larsucosterol Fast Track and Breakthrough Therapy designations. A Phase III study in severe alcoholic hepatitis was initiated in early 2026, with topline results anticipated in 2028. Based on the projected primary completion timeline, regulatory approval could potentially occur in early 2029, followed by a commercial launch later that year.

GSK's GSK4532990

GSK4532990 is an investigational RNA interference (RNAi) therapy targeting HSD17B13, a gene associated with susceptibility to liver disease.

By reducing hepatic HSD17B13 expression, the therapy aims to replicate protective effects associated with loss-of-function variants and potentially reduce liver inflammation and injury. GSK4532990 is currently being evaluated in Phase II clinical development for ALD under an exclusive licensing agreement with Arrowhead Pharmaceuticals.

INT-787

INT-787 is a next-generation oral farnesoid X receptor (FXR) agonist initially developed by Intercept Pharmaceuticals and subsequently incorporated into Alfasigma's liver disease portfolio following its acquisition of Intercept.

The candidate is designed to regulate metabolic, inflammatory, and fibrotic pathways and is currently being evaluated in the Phase IIa FRESH trial for severe alcoholic hepatitis.

Pemvidutide

Pemvidutide, developed by Altimmune, represents an emerging metabolic approach within the ALD pipeline. Its development reflects growing interest in therapies that may address the metabolic dysfunction associated with liver disease.

NTR-101

NTR-101 represents another emerging candidate in the ALD pipeline and contributes to the increasing diversification of treatment approaches being investigated for this high-unmet-need disease area.

The anticipated development and potential launch of these therapies could significantly influence the ALD market landscape over the coming years, particularly if clinical trials demonstrate meaningful improvements in disease outcomes.

Discover more about emerging ALD pipeline therapies @ Alcohol-associated Liver Disease Drugs

Recent Developments in the Alcohol-associated Liver Disease Market

March 2026: Altimmune announced that the use of pemvidutide for ALD, including reducing liver fibrosis, is protected under a pending US provisional patent application. The company plans to pursue a non-provisional US application and corresponding international PCT filing.
November 2025: GSK presented updates from its liver disease pipeline, including GSK4532990 for ALD, at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025.
September 2025: Bausch Health Companies completed its tender offer to acquire DURECT Corporation, purchasing all outstanding shares for USD 1.75 per share in cash, representing approximately USD 63 million upfront, with additional milestone payments potentially reaching USD 350 million based on future net sales.

What Is Alcohol-associated Liver Disease?

Alcohol-associated liver disease refers to a spectrum of liver disorders associated with excessive and prolonged alcohol consumption. The disease can range from alcohol-associated steatosis and hepatitis to fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma.

Chronic alcohol exposure can disrupt liver metabolism and contribute to fat accumulation, inflammation, oxidative stress, and progressive liver scarring. Early-stage disease may improve with alcohol cessation, while advanced disease can result in irreversible liver damage and serious complications.

ALD remains a significant global health burden, with disease risk influenced by factors including alcohol consumption patterns, genetics, obesity, viral hepatitis, and nutritional status.

Alcohol-associated Liver Disease Epidemiology

According to DelveInsight's estimates, the total number of diagnosed prevalent cases of ALD in the 7MM was approximately 12.1 million in 2025.

In the United States, among stage-specific diagnosed prevalent cases of ALD, alcohol-associated steatosis accounted for approximately 3.2 million cases in 2025, followed by alcohol-associated steatohepatitis and alcohol-associated cirrhosis.

The ALD epidemiology analysis covers:

Total diagnosed prevalent cases of ALD
Stage-specific diagnosed prevalent cases of ALD
Gender-specific diagnosed prevalent cases of ALD
Diagnosed prevalent cases of ALD by fibrosis stage
Diagnosed prevalent cases of ALD by fatty liver grade
Total prevalent cases of alcohol use disorder in ALD
Total treated cases of ALD

Alcohol-associated Liver Disease Market Report Metrics

Study Period: 2022–2036
Geographical Coverage: 7MM, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan
ALD Market CAGR: 31.1% during 2026–2036
ALD Market Size in 2025: Approximately USD 145 million
Projected ALD Market Size by 2036: Approximately USD 2.2 billion
Key Companies: Bausch Health, GSK, Alfasigma (Intercept Pharmaceuticals), Evive Biotech, Altimmune, Nterica, and others
Key Therapies: Larsucosterol (DUR-928), GSK4532990, INT-787, F-652, Pemvidutide, NTR-101, and others

Scope of the Alcohol-associated Liver Disease Market Report

The report provides comprehensive insights into:

Alcohol-associated Liver Disease patient population forecast
Alcohol-associated Liver Disease therapeutics market size
Alcohol-associated Liver Disease pipeline analysis
Alcohol-associated Liver Disease market size and trends
Alcohol-associated Liver Disease market opportunities
Alcohol-associated Liver Disease unmet needs
Key opinion leader (KOL) perspectives
Market access and reimbursement
Competitive landscape and emerging therapies

Download the report to understand emerging ALD therapies and market trends @ Alcohol-associated Liver Disease Market Analysis

Alcohol Use Disorder Market

The Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast – 2036 report provides an in-depth assessment of disease epidemiology, treatment trends, market dynamics, and emerging therapies across major markets.

Key companies include Adial Pharmaceuticals, Beckley Psytech, Atai Life Sciences, MediciNova, Imbrium Therapeutics, Tempero Bio, Nxera Pharma, Altimmune, Alkermes, Lundbeck, Otsuka Pharmaceuticals, and others.

Metabolic Dysfunction-Associated Steatohepatitis Market

The Metabolic Dysfunction-Associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast – 2036 report examines the evolving MASH treatment landscape, epidemiology, market trends, emerging therapies, and competitive environment.

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences industry. The company provides comprehensive market research, competitive intelligence, and consulting solutions to support pharmaceutical and biotechnology companies in strategic decision-making.

DelveInsight also provides access to healthcare and pharmaceutical market research reports through its subscription-based platform, PharmDelve.

Contact Us

Kanishk

info@delveinsight.com

2026-09-07

Gastroesophageal Reflux Disease Market in the US to Show Promising Growth at a CAGR of 6% During the Forecast Period (2025–2034) | DelveInsight

DelveInsight's latest Gastroesophageal Reflux Disease Market Insights report provides a comprehensive assessment of the GERD treatment landscape, including current treatment practices, emerging therapies, market share, epidemiology, key market drivers, and market forecasts across the United States, EU4, the United Kingdom, and Japan.

The gastroesophageal reflux disease market continues to face challenges due to a limited number of approved treatment options and persistent unmet needs, particularly among patients who do not achieve adequate symptom control with proton pump inhibitors (PPIs). However, advances in diagnosis and the development of next-generation therapies, including BLI5100 (Tegoprazan) from Braintree Laboratories and Linaprazan glurate from Cinclus Pharma, are expected to support market growth during the forecast period.

Gastroesophageal Reflux Disease Market Key Highlights

The United States GERD market was valued at approximately USD 3.3 billion in 2024.
The US recorded approximately 33 million diagnosed prevalent GERD cases in 2024, highlighting the substantial clinical burden of the disease.
VOQUEZNA (vonoprazan) established an early position as the first P-CAB approved for GERD in the United States and is projected to expand its market presence over the next decade.
BLI5100 (Tegoprazan) and Linaprazan glurate are among the key emerging therapies being evaluated for GERD.
NERD represented the majority of GERD cases in the US in 2024, accounting for approximately 23 million cases, while erosive esophagitis accounted for approximately 10 million cases.
The US GERD market is projected to grow at a CAGR of approximately 6% during 2025–2034.
Key companies involved in the GERD treatment landscape include Braintree Laboratories, Cinclus Pharma, Phathom Pharmaceuticals, Takeda, and others.

Discover more about the GERD market size, forecast, and patient population:
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Key Factors Driving the Growth of the Gastroesophageal Reflux Disease Market

Rising GERD Prevalence

According to DelveInsight's estimates, approximately 33 million diagnosed prevalent cases of GERD were recorded in the United States in 2024. The substantial patient population, combined with ongoing diagnosis and disease-awareness efforts, is expected to support continued demand for GERD therapies.

Growing Adoption of VOQUEZNA

VOQUEZNA (vonoprazan), developed by Phathom Pharmaceuticals, is the first P-CAB approved for GERD in the US. According to the supplied market assessment, its rapid onset and consistent acid suppression may support its use among patients with high acid burden, persistent nocturnal symptoms, or inadequate control during PPI tapering.

Emergence of Next-Generation Therapies

The GERD pipeline is evolving with the development of next-generation P-CABs, including BLI5100 (Tegoprazan) from Braintree Laboratories and Linaprazan glurate from Cinclus Pharma. These candidates are expected to expand treatment options for patients who remain inadequately controlled on conventional PPI therapy.

Increasing Interest in P-CABs

Potassium-competitive acid blockers represent an emerging treatment approach in acid-related gastrointestinal disorders. Their ability to provide rapid and sustained gastric acid suppression has increased interest in this therapeutic class as an alternative or complement to traditional PPIs.

Gastroesophageal Reflux Disease Market Analysis

GERD management continues to be dominated by generic PPIs and H2-receptor antagonists (H2RAs), supported by long-standing physician familiarity and widespread availability.

Despite their widespread use, PPIs may have limitations, including delayed onset of action, variable acid suppression, insufficient nocturnal control, and reduced healing efficacy in some patients with moderate-to-severe erosive esophagitis.

VOQUEZNA (vonoprazan) has emerged as an important addition to the US GERD treatment landscape. As a P-CAB, it provides a different mechanism of acid suppression compared with conventional PPIs and has demonstrated faster and more consistent acid control.

Meanwhile, BLI5100 (Tegoprazan) from Braintree Laboratories and Linaprazan glurate from Cinclus Pharma are advancing through late-stage development. Their potential entry into the market could increase competition within the P-CAB segment and provide additional treatment options for patients who remain inadequately controlled with standard therapy.

Gastroesophageal Reflux Disease Competitive Landscape

The GERD competitive landscape includes marketed therapies as well as emerging candidates designed to improve acid suppression and address persistent treatment gaps.

Braintree Laboratories' BLI5100 (Tegoprazan)

BLI5100 (Tegoprazan) is a next-generation P-CAB being developed for acid-related gastrointestinal disorders. The orally administered therapy is designed to provide rapid and durable gastric acid suppression by directly targeting the proton pump in gastric parietal cells.

According to the supplied information, BLI5100 is currently being evaluated in two Phase III clinical studies in the United States for erosive esophagitis and non-erosive reflux disease (NERD).

If approved, BLI5100 could provide another P-CAB option in the US GERD market and compete with existing therapies in patients seeking effective and sustained acid suppression.

Cinclus Pharma's Linaprazan Glurate

Linaprazan glurate is an investigational next-generation P-CAB and a prodrug of linaprazan. It is being developed with the goal of providing rapid and sustained gastric acid suppression.

The therapy is being investigated for patients with moderate-to-severe erosive GERD and is also being evaluated in combination treatment approaches for Helicobacter pylori infection.

The anticipated entry of these emerging therapies could increase competition in the GERD market and potentially broaden treatment choices for patients who do not achieve adequate control with existing therapies.

Discover more about the latest GERD drugs and emerging therapies @ Gastroesophageal Reflux Disease Drugs Market

Recent Developments in the Gastroesophageal Reflux Disease Market

In October 2025: Cinclus Pharma Holding reported favorable guidance from the US FDA following a Chemistry, Manufacturing, and Controls (CMC) meeting regarding the continued development of linaprazan glurate.
In October 2025: Phathom Pharmaceuticals announced that additional analyses from the pivotal Phase III pHalcon-NERD-301 trial evaluating VOQUEZNA (vonoprazan) tablets in patients with NERD had been published in the American Journal of Gastroenterology.
In August 2025: Braintree Laboratories, a subsidiary of Sebela Pharmaceuticals, reported positive topline results from the 24-week maintenance phase of the pivotal Phase III TRIUMpH study evaluating tegoprazan for GERD.

What is Gastroesophageal Reflux Disease?

Gastroesophageal reflux disease (GERD) is a chronic digestive disorder in which stomach contents, including acid and sometimes bile, flow back into the esophagus. This process, known as acid reflux, can occur when the lower esophageal sphincter does not function properly.

Repeated exposure of the esophagus to gastric contents can cause irritation and inflammation. Common symptoms include heartburn, acid regurgitation, chest discomfort, difficulty swallowing, and chronic cough.

If inadequately managed, GERD may be associated with complications such as esophagitis, esophageal strictures, Barrett's esophagus, and an increased risk of esophageal cancer.

Gastroesophageal Reflux Disease Epidemiology

The GERD epidemiology analysis provides insights into the historical and forecasted patient population across the major markets covered in the report.

In 2024, the United States recorded approximately 33 million diagnosed prevalent GERD cases. NERD represented the majority of cases, with approximately 23 million cases, while erosive esophagitis accounted for approximately 10 million cases.

The report provides epidemiological analysis for the period 2020–2034, segmented by:

Prevalent cases of GERD
Diagnosed prevalent cases of GERD
Gender-specific cases of GERD
Age-specific cases of GERD
Type-specific cases of GERD
Grade-specific cases of GERD
Total treated cases of GERD

Gastroesophageal Reflux Disease Market Report Metrics

Study Period: 2020–2034
Coverage: 7MM
Key Companies: Braintree Laboratories (Sebela Pharmaceuticals), Cinclus Pharma, Phathom Pharmaceuticals, Takeda, and others
Key Therapies: BLI5100 (tegoprazan), linaprazan glurate, VOQUEZNA (vonoprazan), and other emerging therapies
Market Landscape: GERD treatment remains largely dominated by PPIs and H2RAs, while newer potassium-competitive acid blockers (PCABs) are emerging as important treatment options.
Emerging Therapies: BLI5100 (tegoprazan) and linaprazan glurate are late-stage PCAB candidates that could expand treatment options for patients inadequately controlled with conventional PPI therapy.
VOQUEZNA: Phathom Pharmaceuticals' VOQUEZNA (vonoprazan) is approved in the US for erosive GERD and non-erosive GERD, as well as certain H. pylori treatment regimens.
Competitive Outlook: The increasing development of PCAB therapies is expected to intensify competition and provide additional options for patients with persistent or inadequately controlled GERD symptoms.

Scope of the Gastroesophageal Reflux Disease Market Report

The report provides a comprehensive assessment of the GERD market, including:

Therapeutic Assessment: Analysis of current marketed and emerging GERD therapies.
Market Dynamics: Assessment of key market drivers, barriers, forecast assumptions, and emerging treatment opportunities.
Competitive Intelligence: Competitive assessment, SWOT analysis, and market-entry strategies.
Unmet Needs: Identification of major treatment gaps across the GERD landscape.
KOL and Analyst Insights: Expert perspectives on the evolving treatment landscape.
Market Access and Reimbursement: Assessment of reimbursement and market-access considerations across major markets.

Download the report to understand the factors shaping the GERD market over the next decade @
Gastroesophageal Reflux Disease Market Forecast

Key Insights
Report Introduction
Executive Summary of Gastroesophageal Reflux Disease (GERD)
Key Events
Epidemiology and Market Methodology of Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD) Market Overview at a Glance
Disease Background and Overview of Gastroesophageal Reflux Disease (GERD)
Epidemiology and Patient Population of Gastroesophageal Reflux Disease (GERD)
Patient Journey of Gastroesophageal Reflux Disease (GERD)
Marketed Therapies of Gastroesophageal Reflux Disease (GERD)
Emerging Therapies of Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD): Seven Major Market Analysis
Unmet Needs of Gastroesophageal Reflux Disease (GERD)
SWOT Analysis of Gastroesophageal Reflux Disease (GERD)
KOL Views of Gastroesophageal Reflux Disease (GERD)
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

Gastroesophageal Reflux Disease Clinical Trial Analysis

The Gastroesophageal Reflux Disease Pipeline Insight – 2026 report provides comprehensive insights into the pipeline landscape, drug profiles, clinical and non-clinical development stages, and key GERD companies, including Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, and others.

Gastroparesis Market

The Gastroparesis Market Insights, Epidemiology, and Market Forecast – 2036 report provides an in-depth understanding of disease epidemiology, treatment trends, market drivers and barriers, and the competitive landscape, including companies such as Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, and others.

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences industry. The company provides comprehensive end-to-end solutions to support pharmaceutical and biotechnology companies in strategic decision-making, market assessment, competitive intelligence, and commercial planning.

DelveInsight also provides access to healthcare and pharmaceutical market research reports through its subscription-based platform, PharmDelve.

Contact Us

Kanishk

info@delveinsight.com

2026-09-04

IgA Nephropathy Clinical Trial Landscape Intensifies With 25+ Companies and 30+ Pipeline Drugs in Active Development | DelveInsight

The IgA nephropathy clinical trial landscape features more than 30 pipeline therapies across multiple stages of development, with leading companies advancing complement inhibitors, APRIL/BAFF antagonists, CD38-targeted therapies, RNA interference approaches, and other novel mechanisms.

DelveInsight's latest IgA Nephropathy Pipeline Insight 2026 report highlights a rapidly evolving treatment landscape, with more than 25 active companies developing over 30 pipeline drugs for immunoglobulin A nephropathy (IgAN). The report provides comprehensive insights into ongoing clinical trials, emerging therapies, clinical development strategies, competitive dynamics, regulatory milestones, and commercial opportunities shaping the IgAN market.

DelveInsight's IgA Nephropathy Pipeline Insight 2026 report provides global coverage of pipeline therapies across discovery, preclinical, Phase I, Phase II, and Phase III development. The analysis evaluates key clinical trends, emerging treatment approaches, clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving major agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

IgA Nephropathy Clinical Trial Analysis: Key Highlights

More than 25 companies are actively developing 30+ pipeline therapies for IgA nephropathy.
Approximately 12+ IgA nephropathy therapies are in late-stage development, including several Phase III candidates.
Key companies involved in IgAN drug development include Haisco Pharmaceutical Group, Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca/Alexion Pharmaceuticals, F. Hoffmann-La Roche, Ionis Pharmaceuticals, Takeda Pharmaceutical, Arrowhead Pharmaceuticals, NovelMed, Walden Biosciences, Kira Pharmaceuticals, Purespring Therapeutics, Biohaven Therapeutics, Keymed Biosciences, Nanjing Chia-tai Tianqing Pharmaceutical, Rona Therapeutics, Infinimmune, and others.
Promising pipeline therapies include HSK39297, Zigakibart, Povetacicept, Felzartamab, Atacicept, ULTOMIRIS (ravulizumab), Sefaxersen, TAK-079 (mezagitamab), ARO-C3, NM8074 (ruxoprubart), WAL0921, KP104, PS-002, BHV-1400, CM313, NTQ5082, RNK288, IFX 301, and others.
Leading mechanisms of action under investigation include Complement Factor B inhibition, BAFF/APRIL antagonism, anti-APRIL targeting, antibody-dependent cellular cytotoxicity, Gd-IgA1 degradation, RNA interference, and CD38 targeting.
Emerging therapies are being evaluated through different routes of administration, including oral and subcutaneous delivery.

Request a sample and discover the latest advances in IgA nephropathy drug development:
https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

What Is IgA Nephropathy?

IgA nephropathy, also known as Berger's disease, is a chronic kidney disorder characterized by the deposition of immunoglobulin A (IgA) in the glomeruli, the tiny filtering structures responsible for filtering waste from the blood. The accumulation of IgA can trigger inflammation and progressively affect kidney function.

Patients may experience symptoms such as hematuria, proteinuria, high blood pressure, and swelling. Disease severity can vary considerably, with some patients experiencing a relatively stable course while others may progress to chronic kidney disease or kidney failure. Early diagnosis and appropriate disease management are important for preserving kidney function and slowing disease progression.

Learn more about IgA nephropathy drug development @ IgA Nephropathy Treatment

Snapshot of Pipeline IgA Nephropathy Drugs

HSK39297 – Haisco Pharmaceutical Group Co., Ltd. | Phase III | Complement Factor B inhibitor | Oral
Povetacicept – Vertex Pharmaceuticals | Phase III | BAFF and APRIL antagonist | Subcutaneous
Zigakibart – Novartis AG | Phase III | Anti-APRIL | Subcutaneous
CM313 – Keymed Biosciences Co., Ltd. / Timberley Therapeutics | Phase II | CD38 antagonist | Subcutaneous
NTQ5082 – Nanjing Chia-tai Tianqing Pharmaceutical | Phase II | Complement Factor B inhibitor | Oral
BHV-1400 – Biohaven, Ltd. | Phase I | Galactosyl-deficient IgA1 degrader | Subcutaneous
RNK288 – Rona Therapeutics | Preclinical | RNA interference | Not applicable
IFX 301 – Infinimmune | Preclinical | APRIL modulator | Not applicable

Learn more about emerging IgA nephropathy therapies @ IgA Nephropathy Clinical Trials

Analyst Perspective on the IgA Nephropathy Treatment Landscape

According to Stuti Mahajan, Consulting Manager at DelveInsight, the IgA nephropathy treatment landscape is entering a transformative phase as targeted therapies increasingly focus on the underlying biological drivers of the disease.

Therapies such as povetacicept and zigakibart, which target the APRIL/BAFF pathway, together with complement inhibitors such as HSK39297 and innovative approaches such as BHV-1400, could broaden treatment options for patients with IgAN.

These next-generation approaches are being developed with the potential to reduce proteinuria, slow disease progression, reduce dependence on corticosteroid-based treatment, and enable more personalized treatment strategies. The IgAN landscape is expected to increasingly move toward targeted therapies, combination approaches, precision medicine, and earlier intervention.

Recent Developments in the IgA Nephropathy Treatment Space

In May 2026: Vor Bio announced that results from the Phase III TELIGAN trial evaluating telitacicept in IgA nephropathy in China, sponsored by its collaborator RemeGen Co., Ltd., were published in The New England Journal of Medicine.
In March 2026: Vertex Pharmaceuticals announced positive data from a prespecified Week 36 interim analysis of the ongoing Phase III RAINIER trial evaluating povetacicept in IgA nephropathy.
In November 2025: Vertex Pharmaceuticals reported updated Phase I/II data from the RUBY-3 study at the American Society of Nephrology Kidney Week.
In November 2025: Vera Therapeutics reported positive Phase III ORIGIN data for atacicept in IgA nephropathy, with results presented at ASN Kidney Week 2025 and published in The New England Journal of Medicine.
In November 2025: Takeda Pharmaceutical reported data showing sustained preservation of kidney function up to 18 months following treatment with mezagitamab (TAK-079) in patients with primary IgA nephropathy.
In November 2025: Jade Biosciences presented two posters for JADE101, its investigational anti-APRIL monoclonal antibody, at ASN Kidney Week 2025.
In September 2025: Walden Biosciences reported progress supporting the development of WAL0921, including advancement of its ongoing Phase II basket study and regulatory planning activities.

Scope of the IgA Nephropathy Pipeline Report

Coverage: Global
Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Clinical Development Stages: Discovery, Preclinical, Phase I, Phase II, Phase III
Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
Molecule Type: Oligonucleotide, Peptide, Small Molecule
Mechanism of Action: Complement Factor B inhibitor, BAFF/APRIL antagonist, antibody-dependent cellular cytotoxicity, Gd-IgA1 degrader, RNA interference, CD38 antagonist, and others
Key IgA Nephropathy Companies: Eucure (Beijing) Biopharma Co., Ltd., Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca/Alexion Pharmaceuticals, F. Hoffmann-La Roche, Ionis Pharmaceuticals, Takeda Pharmaceutical, Arrowhead Pharmaceuticals, NovelMed, Walden Biosciences, Kira Pharmaceuticals, Purespring Therapeutics, Biohaven Therapeutics, Nanjing Chia-tai Tianqing Pharmaceutical, Keymed Biosciences Co., Ltd., Rona Therapeutics, Infinimmune, and others.
Key IgA Nephropathy Pipeline Therapies: HSK39297, Zigakibart, Povetacicept, Felzartamab, Atacicept, ULTOMIRIS (ravulizumab), Sefaxersen, TAK-079 (mezagitamab), ARO-C3, NM8074 (ruxoprubart), WAL0921, KP104, PS-002, BHV-1400, CM313, NTQ5082, RNK288, IFX 301, and others.

Dive deep into rich insights for new IgA nephropathy treatments, visit @ IgA Nephropathy Drugs

Introduction
Executive Summary
IgA Nephropathy: Overview
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
IgA Nephropathy – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I/II)
Preclinical and Discovery Stage Products
Inactive Products
IgA Nephropathy Key Companies
IgA Nephropathy Key Products
IgA Nephropathy - Unmet Needs
IgA Nephropathy - Market Drivers and Barriers
IgA Nephropathy - Future Perspectives and Conclusion
IgA Nephropathy Analyst Views
Appendix

For further information on the IgA nephropathy cure research, reach out @ Medication for IgA Nephropathy Treatment

Related Reports

IgA Nephropathy Market

DelveInsight's IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2036 report provides an in-depth assessment of disease epidemiology, market trends, market drivers and barriers, and the competitive landscape. Key companies covered include Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca/Alexion Pharmaceuticals, F. Hoffmann-La Roche, Ionis Pharmaceuticals, Takeda Pharmaceutical, Arrowhead Pharmaceuticals, NovelMed, Walden Biosciences, Kira Pharmaceuticals, Purespring Therapeutics, Biohaven Therapeutics, and others.

Acute Kidney Injury Clinical Trial Analysis

DelveInsight's Acute Kidney Injury Pipeline Insight – 2026 report provides comprehensive insights into the AKI pipeline landscape, including clinical and non-clinical stage products and key companies involved in developing novel therapies.

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences industry. The company provides comprehensive market research, consulting, competitive intelligence, and commercial strategy solutions to help pharmaceutical and biotechnology companies make informed business decisions.

DelveInsight also provides access to healthcare and pharmaceutical market research reports through its subscription-based platform, PharmDelve.

Contact Us

Kanishk

info@delveinsight.com

2026-08-28

Polycythemia Vera Market: Growth Momentum Across 7MM to 2034 – DelveInsight

The Polycythemia Vera market is expected to experience continued growth as increasing disease awareness, evolving treatment approaches, and the development of novel therapies create new opportunities. Emerging treatments such as rusfertide, givinostat, bomedemstat, SLN124, sapablursen, and PPMX-T003 are expected to influence the future treatment landscape.

LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- DelveInsight's recently published “Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2034” report provides a comprehensive assessment of the Polycythemia Vera market, including current treatment practices, emerging therapies, epidemiology, market trends, and forecasted market size across the seven major markets (7MM): the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Polycythemia Vera Market Summary

According to DelveInsight's analysis, the Polycythemia Vera market size was approximately USD 1.9 billion in the 7MM in 2024 and is anticipated to grow during the forecast period (2020–2034).
The United States accounted for the highest number of Polycythemia Vera cases among the 7MM in 2023, with approximately 180,000 prevalent cases.
In the EU4 and the United Kingdom, Germany had the highest number of Polycythemia Vera cases, with nearly 25,000 cases in 2023, while Spain reported the lowest number of cases.
According to Orphanet, Polycythemia Vera affects approximately 30 individuals per 100,000 people in Germany, translating to nearly 24,000 affected individuals when extrapolated to the country's population.
Several emerging therapies are expected to influence the Polycythemia Vera treatment landscape, including rusfertide (PTG-300), givinostat, bomedemstat, SLN124, sapablursen, and PPMX-T003.
Key companies involved in Polycythemia Vera drug development include Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals, Incyte Corporation, and others.
The Polycythemia Vera market is expected to benefit from the development of novel therapies targeting disease biology and treatment-related challenges.

Get a Free Sample for the Polycythemia Vera Market Report @
Polycythemia Vera Market Report

Key Factors Driving the Growth of the Polycythemia Vera Market

Rising Disease Burden

Polycythemia Vera continues to represent an important hematological disorder within the myeloproliferative neoplasm landscape. The United States had the highest number of cases among the 7MM in 2023, while Germany represented the leading country within the EU4 and the United Kingdom.

The continued identification and diagnosis of patients, together with growing disease awareness, are expected to support demand for effective long-term treatment options.

Increasing Focus on Novel Treatment Approaches

The Polycythemia Vera treatment landscape is gradually moving toward therapies that can address important disease-management challenges. Existing treatments may not be suitable or sufficiently effective for every patient, creating opportunities for novel mechanisms of action.

According to Kuykendall (2023), up to 25% of patients may develop resistance to or intolerance of hydroxyurea, highlighting an important unmet need and supporting continued research into alternative treatment strategies.

Development of Emerging Therapies

The Polycythemia Vera market is expected to become increasingly competitive as pipeline therapies progress through clinical development. Candidates such as rusfertide, givinostat, bomedemstat, SLN124, sapablursen, and PPMX-T003 are being evaluated for their potential to address important treatment gaps.

Polycythemia Vera Market Analysis

The Polycythemia Vera market is undergoing a period of therapeutic development, supported by advances in understanding disease biology and increasing investment in targeted treatment approaches.

Rusfertide, developed by Protagonist Therapeutics, represents one of the most closely watched emerging therapies in the Polycythemia Vera pipeline. The investigational therapy is a hepcidin mimetic designed to help manage erythrocytosis and reduce the need for frequent phlebotomy.

In January 2026, a New Drug Application (NDA) was filed with the U.S. FDA for rusfertide for the treatment of adults with Polycythemia Vera. The submission was supported by findings from the Phase III VERIFY trial and the Phase II REVIVE trial. The VERIFY study evaluated rusfertide in combination with standard of care and reported positive results across its primary and key secondary endpoints.

The competitive landscape is also being influenced by other emerging therapies. Givinostat, developed by Italfarmaco, received FDA Fast Track designation in May 2025 for Polycythemia Vera. Meanwhile, VGT-1849B, a JAK2 inhibitor developed by Vanda Pharmaceuticals, received FDA Orphan Drug Designation in August 2025 for the treatment of Polycythemia Vera.

These developments highlight the growing focus on therapies with differentiated mechanisms and the potential to improve disease control.

Polycythemia Vera Competitive Landscape

Some of the key companies developing or evaluating therapies for Polycythemia Vera include Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others.

Rusfertide (PTG-300): Protagonist Therapeutics

Rusfertide is an investigational hepcidin mimetic peptide designed to address erythrocytosis in patients with Polycythemia Vera. Its development is focused on improving hematocrit control and reducing the burden associated with phlebotomy.

In August 2025, the FDA granted Breakthrough Therapy Designation to rusfertide for the treatment of erythrocytosis in Polycythemia Vera patients with limited therapeutic options.

Givinostat (ITF2357): Italfarmaco

Givinostat is an investigational therapy being evaluated for Polycythemia Vera. In May 2025, the FDA granted Fast Track designation to givinostat for the indication, supporting its continued development in the Polycythemia Vera treatment landscape.

Bomedemstat: Imago BioSciences

Bomedemstat is another emerging therapy being evaluated for Polycythemia Vera. Its development reflects the increasing focus on novel approaches that may address the underlying biology of myeloproliferative neoplasms.

SLN124: Silence Therapeutics

Silence Therapeutics is developing SLN124, an siRNA-based therapeutic approach targeting pathways relevant to Polycythemia Vera. Additional clinical findings from the SANRECO study have contributed to the evolving understanding of RNA-based approaches in the disease.

Sapablursen: Ionis Pharmaceutical

Ionis Pharmaceutical is developing sapablursen, another investigational candidate being evaluated as part of the broader pipeline of emerging Polycythemia Vera therapies.

PPMX-T003: Perseus Proteomics

PPMX-T003 is an emerging therapeutic candidate being evaluated for Polycythemia Vera, further contributing to the competitive pipeline and diversification of potential treatment mechanisms.

Discover more about the emerging Polycythemia Vera therapies @
Polycythemia Vera Treatment Market

Recent Developments in the Polycythemia Vera Market

January 2026: A New Drug Application was filed with the FDA for rusfertide for the treatment of adults with Polycythemia Vera. The submission was supported by results from the Phase III VERIFY and Phase II REVIVE studies.
November 2025: SOTIO Biotech announced preclinical findings for SOT106 at the Connective Tissue Oncology Society Annual Meeting.
August 2025: The FDA granted Breakthrough Therapy Designation to rusfertide for the treatment of erythrocytosis in Polycythemia Vera.
August 2025: Vanda Pharmaceuticals announced that VGT-1849B received FDA Orphan Drug Designation for Polycythemia Vera.
May 2025: The FDA granted Fast Track designation to givinostat for the treatment of Polycythemia Vera.
March 2025: Protagonist Therapeutics and Takeda announced positive topline results from the Phase III VERIFY study of rusfertide.
December 2024: Silence Therapeutics announced additional results from the Phase I open-label segment of the SANRECO study evaluating divesiran in patients with Polycythemia Vera.
June 2024: AOP Health presented updated findings from the PROUD-PV and CONTINUATION-PV trials evaluating ropeginterferon alfa-2b.
February 2024: Disc Medicine announced that the FDA granted Orphan Drug Designation to DISC-3405 for the treatment of Polycythemia Vera.
January 2024: Takeda and Protagonist Therapeutics established a global licensing and collaboration agreement for rusfertide.

What is Polycythemia Vera?

Polycythemia Vera (PV) is a rare, chronic blood disorder characterized by the abnormal overproduction of blood cells, particularly red blood cells, in the bone marrow. The resulting increase in blood cell concentration can make the blood thicker and increase the risk of complications such as blood clots.

Polycythemia Vera belongs to a group of blood cancers known as myeloproliferative neoplasms, in which the bone marrow produces excessive numbers of blood cells. Long-term disease management focuses on controlling blood counts and reducing the risk of complications.

To know more about the Polycythemia Vera market outlook, drug uptake, treatment scenario, and epidemiology trends @ Polycythemia Vera Market Forecast

Polycythemia Vera Epidemiology

The Polycythemia Vera epidemiology section provides historical, current, and forecasted epidemiological insights across the 7MM during the study period 2020–2034.

In 2023, the United States had approximately 180,000 prevalent Polycythemia Vera cases, representing the largest patient population among the seven major markets.

Within the EU4 and the United Kingdom, Germany had the highest number of cases, with nearly 25,000 cases in 2023.

The Polycythemia Vera epidemiology analysis is segmented into:

Total Prevalence of Polycythemia Vera
Prevalent Cases of Polycythemia Vera by Severity
Gender-specific Prevalence of Polycythemia Vera
Diagnosed Cases of Episodic and Chronic Polycythemia Vera

Download the report to understand Polycythemia Vera epidemiology trends @ Polycythemia Vera Epidemiology Forecast

Polycythemia Vera Drugs Uptake and Pipeline Development Activities

The drug uptake section of the report evaluates the expected adoption of recently launched and emerging therapies during the forecast period. The analysis includes drug-specific market uptake, patient uptake, sales, and market share.

The report also provides an assessment of the Polycythemia Vera pipeline, covering therapies across different stages of clinical development and the companies responsible for their development.

In addition, the pipeline analysis examines important industry developments, including collaborations, licensing agreements, acquisitions, mergers, patent information, and other strategic activities that may influence the market.

Polycythemia Vera Therapies and Key Companies

Rusfertide (PTG-300): Protagonist Therapeutics
Givinostat (ITF2357): Italfarmaco
Bomedemstat: Imago BioSciences
SLN124: Silence Therapeutics
Sapablursen: Ionis Pharmaceutical
PPMX-T003: Perseus Proteomics
PTG-300: Protagonist Therapeutics, Inc.
SLN124: Silence Therapeutics plc
Hydroxyurea: Novartis
Ropeginterferon alfa-2b: PharmaEssentia
PEG-P-INF alpha-2b (P1101): AOP Orphan Pharmaceuticals AG
Ruxolitinib: Incyte Corporation

Discover more about therapies expected to capture Polycythemia Vera market share @ Polycythemia Vera Treatment Market

Polycythemia Vera Market Strengths

The approval of BESREMi in the United States and its potential expansion across additional treatment settings provide an opportunity for interferon-based therapy to strengthen its position in the Polycythemia Vera market.
Increasing adoption of JAKAFI/JAKAVI supports its potential to remain an important therapy for patients requiring second-line treatment.

Polycythemia Vera Market Opportunities

Increasing strategic alliances, including geographical partnerships and licensing agreements, may support the development and commercialization of emerging therapies.
FDA designations such as Breakthrough Therapy Designation and Fast Track designation can support accelerated development pathways for promising candidates.
Novel therapies with differentiated or disease-modifying mechanisms and improved tolerability may address important unmet needs in Polycythemia Vera.

Scope of the Polycythemia Vera Market Report

Study Period: 2020–2034
Coverage: 7MM
Key Polycythemia Vera Companies: Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others
Key Polycythemia Vera Therapies: Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others
Polycythemia Vera Therapeutic Assessment: Current marketed and emerging therapies
Polycythemia Vera Market Dynamics: Market drivers and market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's Five Forces, BCG Matrix, and market entry strategies
Unmet Needs: KOL views, analyst views, market access, and reimbursement

To learn more about companies working in the Polycythemia Vera treatment market @ Polycythemia Vera Clinical Trials and Therapeutic Assessment

Polycythemia Vera Market Report Introduction
Executive Summary for Polycythemia Vera
SWOT Analysis of Polycythemia Vera
Polycythemia Vera Patient Share (%) Overview at a Glance
Polycythemia Vera Market Overview at a Glance
Polycythemia Vera Disease Background and Overview
Polycythemia Vera Epidemiology and Patient Population
Country-Specific Patient Population of Polycythemia Vera
Polycythemia Vera Current Treatment and Medical Practices
Polycythemia Vera Unmet Needs
Polycythemia Vera Emerging Therapies
Polycythemia Vera Market Outlook
Country-Wise Polycythemia Vera Market Analysis (2020–2034)
Polycythemia Vera Market Access and Reimbursement of Therapies
Polycythemia Vera Market Drivers
Polycythemia Vera Market Barriers
Polycythemia Vera Appendix
Polycythemia Vera Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on the life sciences industry. It supports pharma companies by providing comprehensive end-to-end solutions designed to improve business performance.

DelveInsight also offers Healthcare Consulting Services, supporting market analysis, strategic decision-making, and business growth while helping organizations address complex challenges with a practical and data-driven approach.

Contact Us

Kanishk

info@delveinsight.com

Presbyopia Market Key Highlights

Key Factors Driving the Presbyopia Market

Rising Presbyopia Prevalence

Growing Aging Population

Technological Advancements in Vision Correction

Expansion of Emerging Therapies and Devices

Presbyopia Market Analysis

Presbyopia Competitive Landscape

Phentolamine Ophthalmic Solution 0.75%

CorVision

Recent Developments in the Presbyopia Market

What Is Presbyopia?

Presbyopia Epidemiology Segmentation

Presbyopia Market Report Metrics

Scope of the Presbyopia Market Report

Table of Contents

Related Reports

About DelveInsight

Contact Us

Alcohol Use Disorder Market Summary

Key Factors Driving the Growth of the Alcohol Use Disorder Market

Growing Awareness and Early AUD Diagnosis

Rising Focus on Harm Reduction and Personalized Care

Strong AUD Clinical Trial Activity

Alcohol Use Disorder Market Analysis

Alcohol Use Disorder Competitive Landscape

Adial Pharmaceuticals' AD04

Eli Lilly and Company's Brenipatide

MediciNova's MN-166

Altimmune's Pemvidutide

Recent Developments in the Alcohol Use Disorder Market

What is Alcohol Use Disorder?

Alcohol Use Disorder Epidemiology Segmentation

Alcohol Use Disorder Market Report Metrics

Scope of the Alcohol Use Disorder Market Report

Table of Contents

Related Reports

About DelveInsight

Contact Us

Key Takeaways from the Endometriosis Pipeline Report

Endometriosis Overview

Endometriosis Emerging Drugs

HMI-115: Hope Medicine (Nanjing) Co., Ltd.

Merigolix: TiumBio

Nibrozetone (RRx-001): EpicentRx

What the Endometriosis Pipeline Report Provides

Endometriosis Companies

Endometriosis Pipeline by Route of Administration

Endometriosis Pipeline by Molecule Type

Scope of the Endometriosis Pipeline Report

Table of Contents

About DelveInsight

Contact Us

Alcohol-associated Liver Disease Market Key Highlights

Key Factors Driving the Alcohol-associated Liver Disease Market

Rising Global Alcohol Consumption and Changing Drinking Patterns

Increasing Overlap Between ALD, Obesity, and Metabolic Dysfunction

Emergence of Microbiome-based and Precision Medicine Approaches

Diversification of Therapeutic Approaches

Expected Launch of Emerging ALD Therapies

Alcohol-associated Liver Disease Market Analysis

Alcohol-associated Liver Disease Competitive Landscape

Bausch Health's Larsucosterol (DUR-928)

GSK's GSK4532990

INT-787

Pemvidutide

NTR-101

Recent Developments in the Alcohol-associated Liver Disease Market

What Is Alcohol-associated Liver Disease?

Alcohol-associated Liver Disease Epidemiology

Alcohol-associated Liver Disease Market Report Metrics

Scope of the Alcohol-associated Liver Disease Market Report

Related Reports

About DelveInsight

Contact Us

Gastroesophageal Reflux Disease Market Key Highlights

Key Factors Driving the Growth of the Gastroesophageal Reflux Disease Market

Rising GERD Prevalence

Growing Adoption of VOQUEZNA

Emergence of Next-Generation Therapies